Pulmatrix (NSDQ:PULM) said today that it inked an exclusive, worldwide license agreement with Janssen Biotech subsidiary RespiVert.
According to the deal, Pulmatrix will have access to the company’s portfolio of novel kinase inhibitors. The agreement covers respiratory and oncology indications for the drug candidates and Pulmatrix said it plans to take over the portfolio’s global development and commercialization activities.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix inks licensing deal for novel inhaled kinase inhibitors appeared first on MassDevice.